Related Experiment Video
Updated: Jun 19, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Pneumocystis pneumonia in children
Vasilios Pyrgos1, Shmuel Shoham, Emmanuel Roilides
1Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA. walsht@mail.nih.gov
Insights
Pneumocystis pneumonia (PCP) is a serious infection in immunocompromised children, often affecting those with T-lymphocyte deficiencies. Early diagnosis and appropriate treatment are crucial for managing this life-threatening condition.
Area of Science:
- Pediatric Infectious Diseases
- Immunology
- Critical Care Medicine
Background:
- Pneumocystis pneumonia (PCP) poses a significant threat to immunocompromised children.
- Risk factors include lymphoid malignancies, HIV, corticosteroid use, transplantation, and primary immunodeficiencies.
- T-lymphocyte quantitative and qualitative defects are central to susceptibility.
Purpose of the Study:
- To review the diagnosis, treatment, and prophylaxis of Pneumocystis pneumonia in pediatric patients.
- To highlight the importance of understanding PCP pathogenesis for future therapeutic advancements.
Main Methods:
- Diagnosis relies on direct examination or PCR of respiratory secretions.
- Treatment typically involves trimethoprim-sulphamethoxazole.
- Alternative therapies include pentamidine, atovaquone, and specific antibiotic combinations.
Main Results:
- PCP is a life-threatening opportunistic infection in vulnerable pediatric populations.
- Effective diagnostic tools and multiple therapeutic options are available.
- Prophylaxis can mitigate, but not entirely prevent, PCP incidence.
Conclusions:
- Prompt diagnosis and treatment are essential for improving outcomes in pediatric PCP.
- Further research into PCP pathogenesis is vital for developing novel interventions.
- Comprehensive management strategies are necessary for high-risk immunocompromised children.
Abstract:
Pneumocystis pneumonia (PCP) is a life-threatening infection in immunocompromised children with quantitative and qualitative defects in T lymphocytes. At risk are children with lymphoid malignancies, HIV infection, corticosteroid therapy, transplantation and primary immunodeficiency states. Diagnosis is established through direct examination or polymerase chain reaction (PCR) from respiratory secretions. Trimethoprim-sulphamethoxazole is used for initial therapy in most patients, while pentamidine, atovaquone, clindamycin plus primaquine, and dapsone plus trimethoprim are alternatives. Prophylaxis of high-risk patients reduces but does not eliminate the risk of PCP. Improved understanding of the pathogenesis of PCP is important for future advances against this life-threatening infection.
Related Concept Videos
Pneumonia I: Introduction
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia II: Pathophysiology
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Pneumonia III: Complications and Assessment
Respiratory Syncytial Virus Disease